Affidea Romania S.R.L.
- Address
- Bulevardul Tomis 141a, 900591 Constanța, Romania
Non‑small Cell Lung Cancer
At Affidea Romania S.R.L., researchers are exploring new treatment options for non‑small cell lung cancer with KRAS G12C mutations, aiming to improve outcomes by adding targeted therapy to standard chemotherapy.
- KRAS G12C inhibition
- Combination with pembrolizumab
- Standard of care enhancement
The site’s oncology team collaborates with international partners to bring innovative options to patients in Constanta.
Head and Neck Cancer
Clinical studies at the Constanta center focus on recurrent/metastatic head and neck squamous cell carcinoma, testing novel immunotherapy combinations against established checkpoint inhibitors to boost antitumor response.
- PD‑L1 positive patient selection
- Novel immunotherapy combos
- Comparison with dostarlimab
Affidea Romania S.R.L. leverages its expertise in neoplasm research to expand therapeutic possibilities for this challenging disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Celgene Corp.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Affidea Romania S.R.L.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2 | Celgene Corp. | Phase III | Not Recruiting | Jan 2023 | — |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adagrasib | 1 | Unknown | 2025-06-12 | 2025-06-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.